Tristan Rousselle, Founder & Deputy CEO, Aryballe | LinkedIn
Tristan ensures the development of global strategic partnerships and customer relationships to meet Aryballe’s long term vision for the potential of digital olfaction. Prior to founding Aryballe Technologies in 2014, Tristan was the founder and CEO of PX’Therapeutics which specialized in the development of therapeutic proteins. PX’Therapeutics was sold to Aguettan Biotech in 2012. Tristan holds a PhD in Cell Biology from Grenoble University (France).
Digital olfaction mimics the human sense of smell by capturing odor signatures for display and analysis. By integrating digital olfaction sensors into wearable technology, we can use odor data for a host of powerful consumer health use cases—from enhanced stress indicators to hygiene monitoring. A silicon photonic solution functionalized with biosensors is sensitive enough to distinguish hundreds of odors while reducing sensor size and costs. This low cost, high volume solution is enabling innovation in consumer and digital health applications.